

Synthesis and Cytotoxic Activity of Benzophenanthrolinone Analogues of Acronycine

Jean-Bernard BONGUI,^a Abdelhakim ELOMRI,^a Elisabeth SEGUIN,*^a François TILLEQUIN,^b Bruno PFEIFFER,^c Pierre RENARD,^c Alain PIERRE,^d and Ghanem ATASSI^d

Laboratoire de Pharmacognosie de l'Université de Rouen-Haute Normandie,^a Faculté de Pharmacie, 22, Boulevard Gambetta, F-76183 Rouen Cedex, France, Laboratoire de Pharmacognosie de l'Université René Descartes,^b U.M.R./C.N.R.S. n°8638, Faculté des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, F-75006 Paris, France, A.D.I.R. et Compagnie,^c 1 rue Carle Hébert, F-92415 Courbevoie Cedex, France, and Institut de Recherche Servier,^d 11 rue des Moulineaux, F-92150 Suresnes, France. Received February 13, 2001; accepted May 21, 2001

Condensation of either 2-bromobenzoic acid (**4**) or 2-chloro-3-nitrobenzoic acid (**5**) with suitable aminoquinolines **6**—**8** afforded phenylquinolylamines **9**—**13**. Acid mediated cyclization gave the corresponding 12H-benzo[*b*][1,7]phenanthrolin-7-ones **14** and **15**, and 12H-benzo[*b*][1,10]phenanthrolin-7-ones **16**—**18**. Compounds **14**, **16**, and **17** were subsequently *N*-methylated to 6-demethoxyacronycine and acronycine analogues **19**—**21**, whereas reduction of the aromatic nitro group of **18** gave the amino derivative **22**. Unsubstituted 12H-benzo[*b*][1,10]phenanthrolin-7-ones **16**, **17**, **20**, and **21** were devoid of significant cytotoxic activity, whereas **18** and **22**, bearing a nitrogen substituent at position 11, were significantly active. Unsubstituted 12H-benzo[*b*][1,7]phenanthrolin-7-ones **14** and **19**, which include a pyridine nitrogen in the same 4-position as the pyran oxygen of acronycine exhibited cytotoxic activities within the same range of magnitude as acronycine itself.

Key words acronycine; benzophenanthrolinone; cytotoxicity

The acridone alkaloid acronycine (**1**), which was first isolated from *Acronychia baueri* SCHOTT (Rutaceae) in 1948, was later found to be a potent anticancer agent.^{1–5} It is of interest because of its activity against a broad spectrum of solid tumors, including numerous sarcomas, myelomas, carcinomas, and melanomas.^{2–6} Nevertheless, its low water-solubility and moderate potency have severely hampered its clinical trials, which have given so far only poor results.⁷ Consequently, the development of structural analogues possessing a basic nitrogen atom able to give water-soluble salts seems highly desirable.^{8,9}

The replacement of the dimethylpyran D ring of acronycine by a pyridine unit, present in numerous tetracyclic antitumor drugs including the linear ellipticines^{10–12} and olivacines,^{13–15} and their angular 7*H*- and 11*H*-pyridocarbazoles counterparts,^{16–19} appeared to us an attractive way to look for new anticancer candidates. In addition, this approach was consistent with the antitumor activities of several recently described benzophenanthrolinones related to amsacrine.²⁰

This paper deals with the synthesis and cytotoxic properties of 12*H*-benzo[*b*][1,7] and [1,10]phenanthrolinones related to acronycine, and also to 6-demethoxyacronycine (**2**) and 11-aminoacronycine (**3**), which were shown to exhibit cytotoxic activities within the same range of magnitude as acronycine itself.^{9,21}

Chemistry The key-step of our approach was an Ullmann condensation²² of either 2-bromobenzoic acid (**4**) or 2-chloro-3-nitrobenzoic acid (**5**) with suitable aminoquinolines **6**—**8**, to afford the carboxylic phenylquinolylamines **9**—**13**. Cyclization to the corresponding 12*H*-benzo[*b*][1,7]phenan-

throlin-7-ones **14** and **15**, and 12*H*-benzo[*b*][1,10]phenanthrolin-7-ones **16**—**18** was obtained by use of trifluoroacetic anhydride^{21,23} or concentrated sulfuric acid.^{20,24} Methylation at *N*-12 using methyl iodide under classical or phase-transfer catalyzed conditions^{21,23} could only be ensured in the cases of compounds **14**, **16**, and **17**, which bear no bulky nitro substituent at C-11. This reaction gave access to 6-demethoxyacronycine analogues 12-methyl-12*H*-benzo[*b*][1,7]phenanthrolin-7-one (**19**) and 12-methyl-12*H*-benzo[*b*][1,10]phenanthrolin-7-one (**20**), and to acronycine analogue 6-methoxy-12-methyl-12*H*-benzo[*b*][1,10]phenanthrolin-7-one (**21**). Reduction of the nitro group of **18** by catalytic hydrogenation gave 11-amino-12*H*-benzo[*b*][1,10]phenanthrolin-7-one (**22**). In contrast, all attempts towards the reduction of the nitro group of **15** failed, most probably due to the almost complete insolubility of this compound in usual organic solvents.

Pharmacology The study of the biological properties of the new benzophenanthrolin-7-one derivatives was carried out *in vitro* on L1210 murine leukemia cell line. The results (IC₅₀) are reported in Table 1.

The two 12*H*-benzo[*b*][1,7]phenanthrolin-7-ones **14** and **19** were as potent as acronycine. In the 12*H*-benzo[*b*][1,10]-




Chart 1

Table 1. Cytotoxic Activities of Benzophenanthrolinones **14**—**22** Compared with Acronycine Derivatives **1**—**3**

Compound	1	2	3	14	15	16	17	18	19	20	21	22
IC ₅₀ (μM) L1210 cells	10.4	29.9	18.8	15	ins ^{a)}	>100	33	7.7	10.7	72.1	80.8	25.4

a) ins: insoluble.




Chart 2

phenanthroline-7-one series, compounds **18** and **22** were significantly active, whereas **16**, **17**, **20**, and **21** were devoid of antiproliferative activity.

Results and Discussion

Considering the structure-activity relationships, it appears that in the 12*H*-benzo[*b*][1,10]phenanthroline-7-one series, only compounds **18** and **22**, bearing a nitrogen substituent at position 11, exhibited significant cytotoxic activity. Unsubstituted compounds **16**, **17**, **20**, and **21** were devoid of significant activity. Surprisingly, it should be noted that compound **16**, previously prepared as an intermediate in the course of the preparation of ansacrine analogues, was reported to be highly cytotoxic.²⁰

Interestingly, 12*H*-benzo[*b*][1,7]phenanthroline-7-ones **14** and **19**, which include a pyridine nitrogen in the same 4-position as the pyran oxygen of acronycine exhibited cytotoxic activities within the same range of magnitude as acronycine itself. The position of the heteroatom in the heterocyclic D ring fused onto the A–B–C acridone tricyclic system therefore appears to have a dramatic influence on the cytotoxic activity.

Experimental

Chemistry Mass spectra were recorded with a Nermag R-10-10C spectrometer using electron impact (MS) and/or desorption chemical ionization (DCI-MS; reagent gas: NH₃) techniques. UV spectra (λ_{\max} in nm) were determined in spectroscopic grade MeOH on a Beckman Model 34 spectrophotometer. IR spectra (ν_{\max} in cm⁻¹) were obtained in potassium bromide pellets on a Perkin-Elmer 257 instrument. ¹H-NMR (δ [ppm], *J* [Hz]) and ¹³C-NMR spectra were recorded at 300 MHz and 75 MHz, respectively, using a Bruker AC-300 spectrometer. Column chromatography was conducted using flash silica gel 60 Merck (40–63 μ m) with an overpressure of 300 mbars.

N-(5-Quinolyl)anthranilic Acid (9): A mixture containing 5-aminoquinoline (**6**) (216 mg, 1.5 mmol), 2-bromobenzoic acid (**4**) (301.5 mg, 1.5 mmol), potassium acetate (438 mg, 4.47 mmol), copper(II) acetate monohydrate (12 mg, 0.06 mmol), triethylamine (0.25 ml, 1.77 mmol), and 2-propanol (8 ml) was stirred and heated under reflux for 24 h. After cooling and evaporating the solvent, the residue was treated with 1 *N* HCl (30 ml) and extracted with CH₂Cl₂ (3 × 25 ml). The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. Column chromatography on silica gel (CH₂Cl₂/MeOH: 80/20) followed by crystallization from methanol gave **9** (213 mg, 53%) as yellow crystals, mp: 262–263 °C. IR (KBr) cm⁻¹: 3240, 3020, 1680, 1600. UV λ_{\max} (MeOH) nm (log ϵ): 264 (4.19), 342 (3.65). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 6.78 (td, 1H, *J*=8; 2 Hz, C5-H), 6.93 (dd, 1H, *J*=8; 2 Hz, C3-H), 7.32 (td, 1H, *J*=8; 2 Hz, C4-H),




Chart 3

7.53 (dd, 1H, *J*=8; 5 Hz, C3'-H), 7.57 (dd, 1H, *J*=8; 2 Hz, C6'-H), 7.73 (t, 1H, *J*=8 Hz, C7'-H), 7.85 (dd, 1H, *J*=8; 2 Hz, C8'-H), 7.96 (dd, 1H, *J*=8; 2 Hz, C6-H), 8.35 (dd, 1H, *J*=8; 2 Hz, C4'-H), 8.95 (dd, 1H, *J*=5; 2 Hz, C2'-H), 11.20 (br s, 1H, D₂O exch., COOH), 13.10 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 113.8 (s, C-1), 115.2 (d, C-3), 118.7 (d, C-5), 120.6 (d, C-6'), 124.7 ((s, C-4'a), (d, C-3')), 126.4 (d, C-8'), 130.7 (d, C-7') 131.6 (d, C-4'), 132.9 (d, C-6), 135.3 (d, C-4), 137.8 (s, C-5'), 149.2 (s, C-2), 150.0 (s, C-8'a), 151.8 (d, C-2'), 171.4 (s, COOH). MS *m/z*: 264 (M⁺), 249, 219. *Anal.* Calcd for C₁₆H₁₂N₂O₂: C, 72.71; H, 4.58; N, 10.60. Found: C, 72.88; H, 4.50; N, 10.45.

3-Nitro-N-(5-quinolyl)anthranilic Acid (10): Treatment of **6** (175 mg, 1.21 mmol) with 2-chloro-3-nitrobenzoic acid (**5**) (246 mg, 1.22 mmol) under the conditions previously described for **9** afforded **10** (226 mg, 60%) as yellow crystals, mp: 205–206 °C. IR (KBr) cm⁻¹: 3200–2850, 1630, 1620, 1560, 1350. UV λ_{\max} (MeOH) nm (log ϵ): 233 (3.75), 280 (3.68). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 6.79 (dd, 1H, *J*=8; 2 Hz, C6'-H), 7.32 (t, 1H, *J*=8, C5-H), 7.56 (dd, 1H, *J*=8; 5 Hz, C3'-H), 7.70 (t, 1H, *J*=8 Hz, C7'-H), 7.82 (dd,

1H, $J=8$; 2 Hz, C8'-H), 7.90 (dd, 1H, $J=8$; 2 Hz, C6-H), 8.35 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.37 (dd, 1H, $J=8$; 2 Hz, C4'-H), 8.94 (dd, 1H, $J=5$; 2 Hz, C2'-H), 12.41 (br s, 1H, D₂O exch., COOH), 13.62 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 119.3 (d, C-5), 121.0 (d, C-6'), 122.1 (d, C-8'), 123.4 (s, C-1), 123.9 (s, C-4'a), 124.3 (d, C-3'), 124.6 (d, C-7'), 127.1 (d, C-4), 131.9 (s, C-4'), 137.2 (s, C-5'), 137.4 (d, C-6), 139.0 (s, C-2), 140.2 (s, C-3), 149.9 (s, C-8'a), 151.2 (d, C-2'), 170.8 (s, COOH). MS *m/z*: 309 (M⁺), 264. *Anal.* Calcd for C₁₆H₁₁N₃O₄: C, 62.14; H, 3.58; N, 13.59. Found: C, 62.55; H, 3.46; N, 13.42.

N-(8-Quinolyl)anthranilic Acid (**11**): 8-Aminoquinoline (**7**) (216 mg, 1.5 mmol) was reacted with **4** under conditions similar to those described for the preparation of **9** to afford **11** (163 mg, 41%) as yellow crystals, mp: 266—267 °C. IR (KBr) cm⁻¹: 3200—3000, 1670, 1600. UV λ_{\max} (MeOH) nm (log ϵ): 244 (4.08), 261 (4.30), 378 (3.04). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 6.95 (td, 1H, $J=8$; 2 Hz, C5-H), 7.51 (m, 2H, C4-H, C7'-H), 7.54 (t, 1H, $J=8$ Hz, C6'-H), 7.60 (dd, 1H, $J=8$; 5 Hz, C3'-H), 7.75 (dd, 1H, $J=8$; 2 Hz, C5'-H), 7.77 (dd, 1H, $J=8$; 2 Hz, C3-H), 7.79 (dd, 1H, $J=8$; 2 Hz, C6-H), 8.35 (dd, 1H, $J=8$; 2 Hz, C4'-H), 8.90 (dd, 1H, $J=5$; 2 Hz, C2'-H), 11.00 (br s, 1H, D₂O exch., COOH), 13.10 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 112.7 (d, C-3), 116.8 (d, C-5'), 117.7 (s, C-1), 120.0 (d, C-5), 120.2 (d, C-7'), 123.2 (d, C-3'), 128.0 (d, C-4), 128.7 (s, C-4'a), 133.1 (d, C-6), 134.9 (d, C-6'), 137.4 (d, C-4'), 138.8 (s, C-8'), 140.4 (s, C-8'a), 145.5 (s, C-2), 149.6 (d, C-2'), 170.2 (s, COOH). MS *m/z*: 264 (M⁺), 249, 219. *Anal.* Calcd for C₁₆H₁₂N₂O₂: C, 72.71; H, 4.58; N, 10.60. Found: C, 72.80; H, 4.37; N, 10.75.

2-(6-Methoxyquinolin-8-ylamino)benzoic Acid (**12**): 6-Methoxy-8-aminoquinoline (**8**) (353 mg, 2.03 mmol) was reacted with **4** under conditions similar to those described for the preparation of **9** to afford **12** (246 mg, 41%) as yellow crystals, mp: 203 °C. IR (KBr) cm⁻¹: 3150—3000, 1620, 1280. UV λ_{\max} (MeOH) nm (log ϵ): 270 (4.30), 354 (3.76), 375 (3.97). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 3.87 (s, 3H, O-CH₃), 6.90 (d, 1H, $J=2$ Hz, C7'-H), 6.97 (td, 1H, $J=8$; 2 Hz, C5-H), 7.28 (d, 1H, $J=2$ Hz, C5'-H), 7.53 (td, 1H, $J=8$; 2 Hz, C4-H), 7.54 (dd, 1H, $J=8$; 5 Hz, C3'-H), 7.77 (dd, 1H, $J=8$; 2 Hz, C3-H), 7.98 (dd, 1H, $J=8$; 2 Hz, C6-H), 8.23 (dd, 1H, $J=8$; 2 Hz, C4'-H), 8.72 (dd, 1H, $J=5$; 2 Hz, C2'-H), 10.95 (br s, 1H, D₂O exch., COOH), 13.15 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 56.5 (q, O-CH₃), 98.3 (d, C-7'), 104.1 (d, C-5'), 117.4 (2d, C-1, C-3), 120.5 (d, C-5), 123.7 (d, C-3'), 130.9 (s, C-4'a), 133.1 (d, C-4), 135.1 (d, C-6), 136.3 (d, C-4'), 137.0 (s, C-8'), 139.9 (s, C-8'a), 145.0 (s, C-2), 147.0 (d, C-2'), 158.8 (s, C-6'), 170.1 (s, COOH). MS *m/z*: 294 (M⁺), 279, 261, 249. *Anal.* Calcd for C₁₇H₁₄N₂O₃: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.15; H, 4.62; N, 9.20.

3-Nitro-*N*-(8-quinolyl)anthranilic Acid (**13**): Treatment of **7** (175 mg, 1.21 mmol) with **5** (246 mg, 1.22 mmol) under the conditions previously described for the preparation of **9** afforded **13** (187 mg, 50%) as yellow crystals, mp: 205—206 °C. IR (KBr) cm⁻¹: 3200—2900, 1680, 1620, 1560, 1325. UV λ_{\max} (MeOH) nm (log ϵ): 221 (3.90), 289 (3.73). mp: 205—206. ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 6.74 (dd, 1H, $J=8$; 2 Hz, C7'-H), 7.21 (t, 1H, $J=8$, C₅-H), 7.32 (t, 1H, $J=8$ Hz, C6'-H), 7.43 (dd, 1H, $J=8$; 2 Hz, C5'-H), 7.57 (dd, 1H, $J=8$; 5 Hz, C3'-H), 7.93 (dd, 1H, $J=8$; 2 Hz, C6-H), 8.31 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.33 (dd, 1H, $J=8$; 2 Hz, C4'-H), 8.87 (dd, 1H, $J=5$; 2 Hz, C2'-H), 12.55 (br s, 1H, D₂O exch., COOH), 13.70 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 109.8 (d, C-5'), 119.7 (d, C-5), 120.8 (d, C-7'), 123.1 (d, C-3'), 123.8 (s, C-1), 127.5 (d, C-4), 128.6 (d, C-6'), 129.9 (s, C-4'a), 132.6 (s, C-8'a), 137.2 (d, C-6), 137.7 (d, C-4'), 138.5 (s, C-2), 140.1 (s, C-8'), 140.7 (s, C-3), 149.6 (d, C-2'), 171.0 (s, COOH). MS *m/z*: 309 (M⁺), 264. *Anal.* Calcd for C₁₆H₁₁N₃O₄: C, 62.14; H, 3.58; N, 13.59. Found: C, 62.55; H, 3.46; N, 13.42.

12*H*-Benzo[*b*][1,7]phenanthroline-7-one (**14**): A solution of **9** (213 mg, 0.86 mmol) in concentrated sulfuric acid (5 ml) was heated at 100 °C for 5 h. The cooled solution was poured into ice-water and basified with 30% aqueous NaOH. The solution was extracted with 2-butanone (3 × 25 ml). The organic layers were dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. Recrystallization from ethanol gave **14** (143 mg, 67%) as a yellow crystalline product, mp: 293 °C. IR (KBr) cm⁻¹: 3100—3000, 1620. UV λ_{\max} (MeOH) nm (log ϵ): 252 (4.02), 280 (3.75), 303 (3.25), 348 (3.24). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 7.15 (td, 1H, $J=8$; 1 Hz, C9-H), 7.41 (d, 1H, $J=9$ Hz, C5-H), 7.67 (m, 2H, C2-H, C10-H), 7.83 (dd, 1H, $J=8$; 1 Hz, C11-H), 8.37 (dd, 1H, $J=8$; 1 Hz, C8-H), 8.40 (d, 1H, $J=9$ Hz, C6-H), 8.88 (dd, 1H, $J=5$; 2 Hz, C3-H), 9.48 (dd, 1H, $J=8$; 2 Hz, C1-H), 12.50 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 117.6 (s, C-12b), 119.4 (d, C-11), 119.6 (s, C-6a), 122.3 (d, C-2), 122.9 (s, C-7a), 123.5 (d, C-9), 123.6 (d, C-5), 126.7 (d, C-8), 127.3 (d, C-6), 132.7 (d, C-1), 134.2 (d, C-10), 139.4 (s, C-12a), 141.5 (d, C-11a), 151.2 (s, C-4a), 153.4 (d, C-3), 177.0 (s, C-7). MS *m/z*: 246 (M⁺). *Anal.* Calcd for

C₁₆H₁₀N₂O: C, 78.03; H, 4.09; N, 11.37. Found: C, 78.20; H, 4.00; N, 11.49.

11-Nitro-12*H*-benzo[*b*][1,7]phenanthroline-7-one (**15**): Cyclization of **10** (187 mg, 0.60 mmol) under conditions similar to those described for the preparation of **14** afforded **15** (152 mg, 87%) as yellow crystals, mp: 290—291 °C. IR (KBr) cm⁻¹: 3200—2900, 1680, 1500, 1290. UV λ_{\max} (MeOH) nm (log ϵ): 237 (3.62), 283 (3.49). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 7.50 (t, 1H, $J=8$ Hz, C9-H), 7.74 (dd, 1H, $J=8$; 5 Hz, C2-H), 8.04 (d, 1H, $J=9$ Hz, C5-H), 8.67 (d, 1H, $J=9$ Hz, C6-H), 8.71 (dd, 1H, $J=8$; 2 Hz, C3-H), 8.83 (dd, 1H, $J=8$; 2 Hz, C10-H), 8.98 (dd, 1H, $J=8$; 2 Hz, C8-H), 9.18 (dd, 1H, $J=5$; 2 Hz, C1-H), 11.04 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) ϵ : 116.4 (s, C-12b), 121.1 (d, C-5), 121.9 (d, C-2), 125.6 (d, C-9), 125.7 (s, C-6a), 126.5 (d, C-6), 129.2 (d, C-8), 130.7 (s, C-7a), 131.4 (d, C-1), 136.4 (d, C-10), 141.5 (s, C-12a), 143.9 (s, C-11a), 146.1 (s, C-11), 151.4 (s, C-4a), 153.0 (d, C-3), 174.1 (s, C-7). MS *m/z*: 291 (M⁺). *Anal.* Calcd for C₁₆H₉N₃O₃: C, 65.98; H, 3.11; N, 14.43. Found: C, 65.72; H, 3.02; N, 14.26.

12*H*-Benzo[*b*][1,10]phenanthroline-7-one (**16**): Cyclization of **11** (140 mg, 0.53 mmol) under conditions similar to those described for the preparation of **14** afforded **16** (80 mg, 61%) as yellow crystals, mp: 271—272 °C. IR (KBr) cm⁻¹: 3000—2900, 1640. UV λ_{\max} (MeOH) nm (log ϵ): 265 (4.11), 295 (3.90), 320 (3.77), 355 (3.52), 383 (3.32). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 7.36 (td, 1H, $J=8$; 1 Hz, C9-H), 7.66 (d, 1H, $J=9$ Hz, C5-H), 7.75 (td, 1H, $J=8$; 1 Hz, C10-H), 7.82 (dd, 1H, $J=8$; 5 Hz, C3-H), 8.22 (dd, 1H, $J=8$; 1 Hz, C11-H), 8.26 (d, 1H, $J=9$ Hz, C6-H), 8.28 (dd, 1H, $J=8$; 1 Hz, C8-H), 8.48 (dd, 1H, $J=8$; 2 Hz, C4-H), 9.08 (dd, 1H, $J=5$; 2 Hz, C2-H), 12.00 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 119.4 (s, C-6a), 120.3 (d, C-11), 120.8 (d, C-5), 123.3 (s, C-7a), 123.4 (d, C-9), 124.2 (d, C-6), 125.5 (d, C-3), 126.7 (d, C-8), 131.1 (s, C-4a), 134.1 (d, C-10), 137.7 (d, C-4), 139.6 (s, C-12a), 140.0 (s, C-12b), 141.4 (s, C-11a), 150.1 (d, C-2), 177.4 (s, C-7). MS *m/z*: 246 (M⁺). *Anal.* Calcd for C₁₆H₁₀N₂O: C, 78.03; H, 4.09; N, 11.37. Found: C, 78.26; H, 4.35; N, 11.14.

6-Methoxy-12*H*-benzo[*b*][1,10]phenanthroline-7-one (**17**): A solution of **12** (50 mg, 0.17 mmol) and trifluoroacetic anhydride (1 ml, 7.14 mmol) in anhydrous CH₂Cl₂ (10 ml) was stirred at room temperature for 3 d. After evaporation of the solvent, the residue was washed with aqueous NaHCO₃ (5%). The aqueous layer was further extracted with CH₂Cl₂ (2 × 10 ml). The organic layers were dried and evaporated to give **17** (30 mg, 64%) as yellow prisms, mp: 242—243 °C. IR (KBr) cm⁻¹: 3220, 2990, 1630. UV λ_{\max} (MeOH) nm (log ϵ): 263 (4.75), 284 (4.47), 349 (3.94). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 4.05 (s, 3H, O-CH₃), 6.78 (s, 1H, C5-H), 7.33 (td, 1H, $J=8$; 1 Hz, C9-H), 7.48 (dd, 1H, $J=8$; 5 Hz, C3-H), 7.50 (dd, 1H, $J=8$; 1 Hz, C11-H), 7.67 (td, 1H, $J=8$; 1 Hz, C10-H), 8.01 (dd, 1H, $J=8$; 1 Hz, C8-H), 8.52 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.79 (dd, 1H, $J=5$; 2 Hz, C2-H), 9.20 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 56.0 (q, O-CH₃), 95.9 (d, C-5), 111.5 (s, C-6a), 116.7 (d, C-11), 122.5 (d, C-9), 124.3 (d, C-3), 124.7 (s, C-7a), 127.2 (d, C-8), 130.5 (s, C-4a), 132.7 (d, C-10), 134.2 (s, C-12a), 138.0 (s, C-12b), 139.9 (s, C-11a), 145.6 (d, C-2), 158.1 (s, C-6), 177.1 (s, C-7). MS *m/z*: 276 (M⁺), 261. *Anal.* Calcd for C₁₇H₁₂N₂O₂: C, 73.90; H, 4.38; N, 10.14. Found: C, 73.55; H, 4.32; N, 10.25.

11-Nitro-12*H*-benzo[*b*][1,10]phenanthroline-7-one (**18**): Cyclization of **13** (175 mg, 0.57 mmol) under conditions similar to those described for the preparation of **14** afforded **18** (143 mg, 70%) as orange crystals, mp: 275—276 °C. IR (KBr) cm⁻¹: 3100—3000, 1620, 1520, 1330. UV λ_{\max} (MeOH) nm (log ϵ): 234 (3.80), 272 (3.56). ¹H-NMR (300 MHz, DMSO-*d*₆) δ : 7.56 (t, 1H, $J=8$ Hz, C9-H), 7.78 (d, 1H, $J=9$ Hz, C5-H), 7.81 (dd, 1H, $J=8$; 5 Hz, C3-H), 8.41 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.42 (d, 1H, $J=9$ Hz, C6-H), 8.89 (dd, 1H, $J=8$; 2 Hz, C10-H), 8.98 (dd, 1H, $J=8$; 2 Hz, C8-H), 9.14 (dd, 1H, $J=5$; 2 Hz, C2-H), 10.92 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ : 119.7 (s, C-6a), 122.4 (d, C-5), 123.2 (d, C-6), 123.4 (d, C-3), 126.3 (d, C-9), 127.9 (s, C-7a), 131.4 (s, C-4a), 132.7 (d, C-8), 136.1 (d, C-10), 136.4 (d, C-11a), 138.1 (d, C-4), 138.2 (s, C-11), 140.7 ((s, C-12a), (s, C-12b)), 151.5 (d, C-2), 176.6 (s, C-7). MS *m/z*: 291 (M⁺). *Anal.* Calcd for C₁₆H₉N₃O₃: C, 65.98; H, 3.11; N, 14.43. Found: C, 65.81; H, 2.94; N, 14.32.

12-Methyl-12*H*-benzo[*b*][1,7]phenanthroline-7-one (**19**): To a solution of **14** (127 mg, 0.52 mmol), benzyltriethylammonium chloride (330 mg, 1.45 mmol), and 30% aqueous NaOH (3 ml) in 2-butanone (3 ml) was added methyl iodide (0.050 ml, 0.80 mmol). The mixture was stirred and refluxed for 3 h. The cooled solution was diluted with a mixture of CH₂Cl₂/H₂O (10 ml/5 ml). The aqueous solution was extracted with CH₂Cl₂. The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure to afford **19** (54 mg, 40%) as yellow crystals, mp: 290 °C. IR (KBr) cm⁻¹: 3000, 2990, 1660, 1280, 750. UV λ_{\max} (MeOH) nm (log ϵ): 254 (4.45), 290 (4.71), 332 (3.90), 350 (3.66), 376 (3.84). ¹H-NMR (300

MHz, DMSO- d_6) δ : 4.32 (s, 3H, N-CH₃), 7.42 (td, 1H, $J=8$; 1 Hz, C9-H), 7.50 (dd, 1H, $J=8$; 5 Hz, C2-H), 7.66 (d, 1H, $J=9$ Hz, C5-H), 7.82 (td, 1H, $J=8$; 2 Hz, C10-H), 7.91 (dd, 1H, $J=8$; 2 Hz, C11-H), 8.54 (dd, 1H, $J=8$; 2 Hz, C8-H), 8.67 (d, 1H, $J=9$ Hz, C6-H), 8.69 (dd, 1H, $J=5$; 2 Hz, C3-H), 9.02 (dd, 1H, $J=8$; 2 Hz, C1-H). ¹³C-NMR (75 MHz, DMSO- d_6) δ : 44.6 (q, N-CH₃), 117.0 (d, C-11), 118.9 (d, C-2), 119.8 (d, C-12b), 121.3 (s, C-6a), 122.9 (d, C-9), 124.1 (s, C-7a), 124.5 (d, C-5), 126.7 (d, C-8), 127.1 (d, C-6), 133.6 (d, C-1), 135.0 (d, C-10), 143.8 (s, C-12a), 145.7 (s, C-11a), 151.5 (d, C-3), 152.2 (s, C-4a), 177.4 (s, C-7). MS m/z : 260 (M⁺), 245. Anal. Calcd for C₁₇H₁₂N₂O: C, 78.44; H, 4.65; N, 10.76. Found: C, 78.68; H, 4.36; N, 10.80.

12-Methyl-12H-benzo[*b*][1,10]phenanthrolin-7-one (**20**): Methylation of **16** (90 mg, 0.36 mmol) under conditions similar to those described for the preparation of **19** afforded **20** (43 mg, 46%) as yellow crystals, mp: 281 °C. IR (KBr) cm⁻¹: 3100—3000, 1630, 1290, 750. UV λ_{\max} (MeOH) nm (log ϵ): 252 (4.55), 282 (4.65), 344 (4.04), 363 (3.97), 388 (3.99). ¹H-NMR (300 MHz, DMSO- d_6) δ : 4.46 (s, 3H, N-CH₃), 7.36 (td, 1H, $J=8$; 1 Hz, C9-H), 7.51 (dd, 1H, $J=8$; 5 Hz, C3-H), 7.65 (d, 1H, $J=9$ Hz, C5-H), 7.73 (td, 1H, $J=8$; 1 Hz, C10-H), 7.76 (dd, 1H, $J=8$; 1 Hz, C11-H), 8.18 (dd, 1H, $J=8$; 1 Hz, C8-H), 8.53 (d, 1H, $J=9$ Hz, C6-H), 8.55 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.93 (dd, 1H, $J=5$; 2 Hz, C2-H). ¹³C-NMR (75 MHz, DMSO- d_6) δ : 43.6 (q, N-CH₃), 117.0 (d, C-11), 121.3 (d, C-5), 122.2 (d, C-9), 122.5 (d, C-6), 122.6 (d, C-6a), 122.8 (d, C-7a), 123.8 (d, C-3), 126.7 (d, C-8), 132.2 (s, C-4a), 133.3 (d, C-10), 136.1 (d, C-4), 141.5 (s, C-12a), 142.3 (s, C-12b), 145.1 (s, C-11a), 146.6 (d, C-2), 177.6 (s, C-7). MS m/z : 260 (M⁺), 245. Anal. Calcd for C₁₇H₁₂N₂O: C, 78.44; H, 4.65; N, 10.76. Found: C, 78.32; H, 4.71; N, 10.51.

6-Methoxy-12-methyl-12H-benzo[*b*][1,10]phenanthrolin-7-one (**21**): Methyl iodide (0.4 ml, 6.38 mmol) was added to a solution of **17** (55 mg, 0.2 mmol) and sodium hydride (300 mg, 12.5 mmol) in dimethylformamide (7 ml). The reaction mixture was stirred and refluxed under N₂ for 24 h. After dilution with H₂O (15 ml), the solution was extracted with CH₂Cl₂ (20 ml). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure to afford **21** (16 mg, 27%) as a yellow crystalline product, mp: 285 °C. IR (KBr) cm⁻¹: 3200, 2990, 1595, 1490, 1215, 760. UV λ_{\max} (MeOH) nm (log ϵ): 266 (4.41), 283 (4.28), 385 (3.79). ¹H-NMR (300 MHz, DMSO- d_6) δ : 4.13 (s, 3H, N-CH₃), 4.37 (s, 3H, O-CH₃), 6.85 (s, 1H, C5-H), 7.35 (td, 1H, $J=8$; 1 Hz, C9-H), 7.57 (dd, 1H, $J=8$; 5 Hz, C3-H), 7.68 (dd, 1H, $J=8$; 1 Hz, C11-H), 7.74 (td, 1H, $J=8$; 1 Hz, C10-H), 8.05 (dd, 1H, $J=8$; 1 Hz, C8-H), 8.58 (dd, 1H, $J=8$; 2 Hz, C4-H), 8.80 (dd, 1H, $J=5$; 2 Hz, C2-H). ¹³C-NMR (75 MHz, DMSO- d_6) δ : 43.2 (q, N-CH₃), 56.7 (q, O-CH₃), 96.7 (d, C-5), 113.2 (s, C-6a), 114.5 (d, C-11), 122.1 (d, C-9), 123.2 (d, C-3), 123.8 (s, C-7a), 127.3 (d, C-8), 130.9 (s, C-4a), 131.4 (d, C-10), 133.7 (d, C-4), 136.5 (s, C-12a), 141.3 (s, C-12b), 142.1 (d, C-2), 143.2 (s, C-11a), 158.6 (s, C-6), 177.3 (s, C-7). MS m/z : 290 (M⁺), 261. Anal. Calcd for C₁₈H₁₄N₂O₂: C, 74.47; H, 4.86; N, 9.65. Found: C, 74.59; H, 4.81; N, 9.72.

11-Amino-12H-benzo[*b*][1,10]phenanthrolin-7-one (**22**): To a solution of **18** (50 mg, 0.17 mmol) in DMF (15 ml), was added 10% Pd/C (20 mg). The mixture was stirred at room temperature for 2 h under H₂ (1 atm.), filtered and evaporated under reduced pressure. Column chromatography of the residue on silica gel (solvent: CH₂Cl₂/MeOH: 97/3: v/v) gave **22** (40 mg, 90%) as yellow crystals, mp: 259—260 °C. IR (KBr) cm⁻¹: 3150, 2980, 1590, 1430, 1595. UV λ_{\max} (MeOH) nm (log ϵ): 223 (3.56), 245 (3.19). ¹H-NMR (300 MHz, DMSO- d_6) δ : 5.85 (s, 2H, NH₂), 7.15 (dd, 1H, $J=8$; 2 Hz, C10-H), 7.17 (t, 1H, $J=8$ Hz, C9-H), 7.66 (dd, 1H, $J=8$; 2 Hz, C8-H), 7.68 (d, 1H, $J=9$ Hz, C5-H), 7.84 (dd, 1H, $J=8$; 5 Hz, C3-H), 8.26 (d, 1H, $J=9$ Hz, C6-H), 8.52 (dd, 1H, $J=8$; 2 Hz, C4-H), 9.10 (dd, 1H, $J=5$; 2 Hz, C2-H), 10.80 (br s, 1H, D₂O exch., NH). ¹³C-NMR (75 MHz, DMSO- d_6) δ : 115.3 (d, C-9), 118.6 (s, C-6a), 118.8 (d, C-5), 120.6 (d, C-6), 123.7 (d, C-3), 124.0 (d, C-10), 125.3 (d, C-8), 130.5 (s, C-7a), 130.6 (s, C-4a), 137.6 (d, C-4), 138.1 (s, C-11a), 138.8 (s, C-11), (s, C-12a), 139.5 (s, C-12b), 150.0 (d, C-2), 177.4 (s, C-7). MS m/z : 261 (M⁺). Anal. Calcd for C₁₆H₁₁N₃O: C, 73.55; H, 4.24; N, 16.08. Found: C, 73.69; H, 4.33; N, 15.97.

Biological Pharmacology Cytotoxicity: Murine leukemia L1210 cells from the American Type Culture Collection (Rockville Pike, MD) were

grown in RPMI medium 1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin and 10 mM HEPES buffer (pH 7.4). The cytotoxicity was measured by microculture tetrazolium assay essentially as described.²⁵ Cells were exposed to graded concentrations of the test drug (nine serial dilutions in triplicate) for 48 h. Results are expressed as IC₅₀ (mean, $n=3$), which is defined as the drug concentration inhibiting the absorbance by 50% with respect to that of untreated cells.

Acknowledgments Financial support from the Comité Régional de Haute-Normandie de la Ligue Nationale contre le Cancer is gratefully acknowledged.

References

- Hughes G. K., Lahey F. N., Price J. R., Webb L. J., *Nature* (London), **162**, 223—224 (1948).
- Svoboda G. H., *Lloydia*, **29**, 206—224 (1966).
- Svoboda G. H., Poore G. A., Simpson P. J., Boder G. B., *J. Pharm. Sci.*, **55**, 758—768 (1966).
- Suffness M., Cordell G. A., "The Alkaloids," Vol. 25, ed. by Brossi A., Academic Press, New York, 1985, pp. 1—355.
- Tillequin F., Michel S., Skaltsounis A.-L., "Alkaloids: Chemical and Biological Perspectives," Vol. 12, ed. by Pelletier S. W., Elsevier, New York, 1998, pp. 1—102.
- Dorr R. T., Liddil J. D., Von Hoff D. D., Soble M., Osborne C. K., *Cancer Res.*, **49**, 340—344 (1989).
- Scarffè J. H., Beaumont A. R., Gowther D., *Cancer Treat. Rep.*, **67**, 93—94 (1983).
- Schneider J., Evans E. L., Grunberg E., Fryer R. I., *J. Med. Chem.*, **15**, 266—270 (1972).
- Elomri A., Michel S., Koch M., Seguin E., Tillequin F., Pierré A., Atassi Gh., *Chem. Pharm. Bull.*, **47**, 1604—1606 (1999).
- Le Pecq J. B., Dat-Xuong N., Gosse C., Paoletti C., *Proc. Natl. Acad. Sci. U.S.A.*, **71**, 5078—5082 (1974).
- Honda T., Kato M., Inoue M., Shimamoto T., Shima K., Nakanishi T., Yoshida T., Noguchi T., *J. Med. Chem.*, **31**, 1295—1305 (1988).
- Guillonnet C., Pierré A., Charton Y., Guilbaud N., Kraus-Berthier L., Léonce S., Michel A., Bisagni E., Atassi Gh., *J. Med. Chem.*, **42**, 2191—2203 (1999).
- Jaszold-Howorko R., Landras C., Pierré A., Atassi Gh., Guilbaud N., Kraus-Berthier L., Léonce S., Rolland Y., Prost J., Bisagni E., *J. Med. Chem.*, **37**, 2445—2452 (1994).
- Léonce S., Pérez V., Casabianca-Pignède M. R., Anstett M., Bisagni E., Pierré A., Atassi Gh., *Invest. New Drugs*, **14**, 169—180 (1996).
- Pierré A., Atassi Gh., Devissaguet M., Bisagni E., *Drugs Future*, **22**, 53—59 (1997).
- Pelaprat D., Oberlin R., Le Guen I., Roques B. P., Le Pecq J. B., *J. Med. Chem.*, **23**, 1330—1335 (1980).
- Pelaprat D., Delbarre A., Le Guen I., Roques B. P., Le Pecq J. B., *J. Med. Chem.*, **23**, 1336—1343 (1980).
- Lescot E., Muzard G., Markovits J., Bellény J., Roques B. P., Le Pecq J. B., *J. Med. Chem.*, **29**, 1731—1737 (1986).
- Léon P., Garbay-Jaureguiberry C., Barsi M. C., Le Pecq J. B., Roques B. P., *J. Med. Chem.*, **30**, 2074—2080 (1987).
- Llama E., Del Campo C., Capo M., Anadon M., *J. Pharm. Sci.*, **82**, 262—265 (1993).
- Elomri A., Michel S., Tillequin F., Koch M., *Heterocycles*, **34**, 799—806 (1992).
- Ullmann F., *Ber. Dtsch. Chem. Ges.*, **36**, 2382—2384 (1903).
- Loughhead D. G., *J. Org. Chem.*, **55**, 2245—2246 (1990).
- Sánchez E., Del Campo C., Avedaño C., Llama E., *Heterocycles*, **31**, 2003—2010 (1990).
- Pierré A., Kraus-Berthier L., Atassi Gh., Cros S., Poupon M. F., Lavielle G., Berlion M., Bizzari J. P., *Cancer Res.*, **51**, 2312—2318 (1991).